73/100BCME Group stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for CME Group is 321.63, 0.7% above the current price of 319.28. Their targets range from 270.00 to 367.00.
Of the 15 firms that rated CME Group in the past 12 months, 8 rate it buy or strong buy, 6 hold and 1 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 270.00 to 367.00, with an average of 321.63.
| Buy | 8 | |
| Hold | 6 | |
| Sell | 1 |
12-month price target
| Highest target | 367.00 |
| Average target | 321.63 |
| Lowest target | 270.00 |
| Current price | 319.28 |
CME Group price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their CME Group price target and rating?
How analysts rate CME Group, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
8 of 15 firms rate it buy now, against 6 of 12 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
CME Group analyst upgrades, downgrades and price targets
The latest rating change came on 22 October 2026, when JP Morgan upgraded CME Group from Underweight to Overweight. The most recent new target came from Piper Sandler on 22 October 2026: 330.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 22 Oct 2026 | Piper Sandler | Reiterated · Overweight | 295.00 → 330.00 | +11.9% | 295.79 |
| 22 Oct 2026 | Wells Fargo Daniel Welden | Reiterated · Overweight | 315.00 → 333.00 | +5.7% | 295.79 |
| 22 Oct 2026 | Morgan Stanley Michael Cyprys | Reiterated · Overweight | 337.00 → 359.00 | +6.5% | 295.79 |
| 22 Oct 2026 | CLSA | — | 367.00 | — | 295.79 |
| 22 Oct 2026 | Barclays Benjamin Budish | Reiterated · Equal Weight | 281.00 → 321.00 | +14.2% | 295.79 |
| 22 Oct 2026 | JP Morgan | Upgraded · Underweight → Overweight | — | — | — |
| 14 Oct 2026 | Wells Fargo Daniel Welden | Reiterated · Overweight | 301.00 → 315.00 | +4.7% | 278.03 |
| 9 Oct 2026 | Morgan Stanley | Reiterated · Overweight | 330.00 → 337.00 | +2.1% | 276.44 |
| 7 Oct 2026 | Barclays | Reiterated · Equal Weight | 316.00 → 281.00 | -11.1% | 270.18 |
| 5 Oct 2026 | UBS Alex Kramm | Reiterated · Neutral | 260.00 → 270.00 | +3.8% | 263.14 |
| 1 Oct 2026 | Wells Fargo Daniel Welden | — | 301.00 | — | 265.10 |
| 19 Aug 2026 | Deutsche Bank | Downgraded · Buy → Hold | 300.00 → 270.00 | -10.0% | 271.54 |
| 23 Jul 2026 | Morgan Stanley Michael Cyprys | Reiterated · Overweight | 324.00 → 330.00 | +1.9% | 252.80 |
| 15 Jul 2026 | Piper Sandler | Reiterated · Overweight | 320.00 → 295.00 | -7.8% | 243.61 |
| 10 Jul 2026 | Morgan Stanley | Reiterated · Overweight | 353.00 → 324.00 | -8.2% | 237.46 |
| 6 Jul 2026 | UBS Alex Kramm | Reiterated · Neutral | 310.00 → 260.00 | -16.1% | 236.60 |
| 18 Jun 2026 | Keefe, Bruyette & Woods | Upgraded · Market Perform → Outperform | — | — | — |
| 17 Jun 2026 | Piper Sandler Patrick Moley | — | 329.00 → 320.00 | -2.7% | 248.12 |
| 15 Jun 2026 | Piper Sandler Patrick Moley | — | 329.00 | — | 267.85 |
| 11 Jun 2026 | Redburn Partners | — | 323.00 | — | 263.80 |
| 11 Jun 2026 | Rothschild & Co | Upgraded · Neutral → Buy | — | — | — |
| 5 Jun 2026 | Erste Group | Downgraded · Buy → Hold | — | — | — |
| 23 Apr 2026 | Morgan Stanley Michael Cyprys | Reiterated · Overweight | 362.00 → 353.00 | -2.5% | 282.45 |
| 23 Apr 2026 | Barclays | Reiterated · Equal Weight | 312.00 → 316.00 | +1.3% | 285.71 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Overweight | 340.00 → 362.00 | +6.5% | 294.82 |
| 4 Mar 2026 | Argus Research | Downgraded · Buy → Hold | — | — | — |
| 6 Feb 2026 | UBS | Reiterated · Neutral | 280.00 → 310.00 | +10.7% | 297.38 |
| 5 Feb 2026 | RBC Capital Ashish Sabadra | Reiterated · Sector Perform | 302.00 | — | 300.42 |
| 5 Feb 2026 | Morgan Stanley | Reiterated · Overweight | 319.00 → 340.00 | +6.6% | 294.62 |
| 5 Feb 2026 | Barclays Benjamin Budish | Reiterated · Equal Weight | 304.00 → 312.00 | +2.6% | 294.62 |
| 15 Jan 2026 | Morgan Stanley | Reiterated · Overweight | 320.00 → 319.00 | -0.3% | 273.41 |
| 14 Jan 2026 | TD Cowen | Upgraded · Hold → Buy | — | — | — |
| 22 Dec 2025 | Morgan Stanley Michael Cyprys | Reiterated · Overweight | 314.00 → 320.00 | +1.9% | 269.09 |
| 12 Dec 2025 | Barclays | Reiterated · Equal Weight | 280.00 → 304.00 | +8.6% | 272.42 |
CME Group EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect CME Group's EPS to grow 8.5% a year until 2028, slower than over the last 5 years (13.7% a year) and the last 3 years (14.7%).
Analysts expect CME Group's revenue to grow 6.9% a year until 2028, about as fast as over the last 5 years (6.0% a year) and the last 3 years (9.1%).
Revenue
EPS
Does CME Group beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 1.6% off the result, either way, and their revenue estimate 0.6%, over the last 12 quarters.
- EPS beats
- 69 / 96
- Revenue beats
- 64 / 95
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +1.6%
- Since
- January 2003
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 21 Oct 2026 | 2.99 | 3.02 | +1.0% | 1.71B | 1.74B | +1.3% |
| Q2 FY2026 | 22 Jul 2026 | 2.91 | 2.99 | +2.7% | 1.68B | 1.71B | +1.4% |
| Q1 FY2026 | 22 Apr 2026 | 3.34 | 3.36 | +0.6% | 1.87B | 1.88B | +0.3% |
| Q4 FY2025 | 4 Feb 2026 | 2.75 | 2.77 | +0.7% | 1.65B | 1.65B | +0.1% |
| Q3 FY2025 | 22 Oct 2025 | 2.63 | 2.68 | +1.9% | 1.53B | 1.54B | +0.5% |
| Q2 FY2025 | 23 Jul 2025 | 2.91 | 2.96 | +1.7% | 1.69B | 1.69B | +0.4% |
| Q1 FY2025 | 23 Apr 2025 | 2.80 | 2.80 | 0.0% | 1.64B | 1.64B | -0.2% |
| Q4 FY2024 | 12 Feb 2025 | 2.46 | 2.52 | +2.4% | 1.51B | 1.53B | +0.7% |
| Q3 FY2024 | 23 Oct 2024 | 2.66 | 2.68 | +0.8% | 1.59B | 1.58B | -0.3% |
| Q2 FY2024 | 24 Jul 2024 | 2.53 | 2.56 | +1.2% | 1.53B | 1.53B | -0.1% |
| Q1 FY2024 | 24 Apr 2024 | 2.45 | 2.50 | +2.0% | 1.48B | 1.49B | +0.8% |
| Q4 FY2023 | 14 Feb 2024 | 2.28 | 2.37 | +3.9% | 1.43B | 1.44B | +0.8% |
CME Group stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If CME Group's earnings keep growing at the 8.4% a year analysts expect to FY2028, it would earn about 16.76 a share in FY2030. At the P/E it has traded at over the last five years (22.7 to 31.3) that is 380.24 to 524.37 a share, or 424.93 at its average P/E of 25.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 12.40 | 281.35 | 314.42 | 387.99 |
| FY2027 | 13.25 | 300.70 | 336.04 | 414.68 |
| FY2028 | 14.27 | 323.77 | 361.83 | 446.50 |
| FY2029 (extrapolated) | 15.46 | 350.87 | 392.11 | 483.87 |
| FY2030 (extrapolated) | 16.76 | 380.24 | 424.93 | 524.37 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 8.4% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (22.7, 25.4, 31.3).
Is CME Group stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
CME Group's P/E of 26.0 is above the middle of its 5-year range (18.5 to 36.7, median 25.0). Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history. Buyers pay more for each point of growth than usual: a PEG of 3.1 on expected growth against 1.8 on its median P/E and past five years' growth. At its usual P/E (26.0 × EPS of 11.42), CME Group's fair value is 297.15; the price, 319.28, is 7.4% above it. The EPS is without 0.84 a share of one-off gains in its other income, which the business does not repeat. Its forward P/E, on the consensus for FY2026, is 25.8.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (19.9 and 43.7). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 26.04
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 25.02
- Five-year P/E range
- 18.5 – 36.7
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 25.75
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.11
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +0.7%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.